SPHK2 and neoplasm: We have previously shown that the sphingosine kinase 2 selective inhibitor ABC294640 has broad anti-tumor activity [22, 23], that its effects mimic SphK2 ablation, and that loss of SphK2 impacts tumor growth more profoundly than loss of SphK1 [24].